QIAGEN jumps as new FDA clearance bolsters its syndromic-testing growth story

QIAGEN N.V. (QGEN) is up 6.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor reaction to QIAGEN’s recent FDA clearance for a new QIAstat-Dx bloodstream infection panel, which completes the company’s U.S. bloodstream infection menu and strengthens one of its priority growth platforms. The move may also reflect renewed confidence in the business after management recently delivered quarterly results above its outlook and kept full-year guidance in place.

Details:

Late in September, the company said the FDA cleared a new bacteria detection panel for QIAstat-Dx, giving it a fuller U.S. offering for rapid bloodstream infection testing.

The newly cleared panel expands QIAGEN’s ability to identify gram-negative bacteria and antimicrobial resistance markers from positive blood cultures, which can improve the commercial appeal of the system.

In its most recent quarterly update, QIAGEN said second-quarter 2026 sales and adjusted earnings per share came in above expectations, while full-year guidance was reaffirmed.

The stock had closed the prior session near $42 before climbing into the mid-$44 range intraday, suggesting buyers tied the recent product and execution news to a stronger near-term growth outlook.

Sources:

QIAGEN, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$QGEN Hedge Fund Activity

We have seen 203 institutional investors add shares of $QGEN stock to their portfolio, and 145 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRINCIPAL FINANCIAL GROUP INC added 6,643,158 shares (+120281.7%) to their portfolio in Q2 2026, for an estimated $259,747,477
NORGES BANK added 4,325,135 shares (+inf%) to their portfolio in Q2 2026, for an estimated $169,112,778
BOSTON PARTNERS removed 3,597,424 shares (-99.2%) from their portfolio in Q2 2026, for an estimated $140,659,278
DEUTSCHE BANK AG\ removed 3,416,149 shares (-61.0%) from their portfolio in Q2 2026, for an estimated $133,571,425
MILLENNIUM MANAGEMENT LLC added 3,247,768 shares (+543.3%) to their portfolio in Q2 2026, for an estimated $126,987,728
HELIKON INVESTMENTS LTD added 3,085,155 shares (+inf%) to their portfolio in Q2 2026, for an estimated $120,629,560
GOLDMAN SACHS GROUP INC added 3,052,347 shares (+219.4%) to their portfolio in Q2 2026, for an estimated $119,346,767

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$QGEN Price Targets

Multiple analysts have issued price targets for $QGEN recently. We have seen 7 analysts offer price targets for $QGEN in the last 6 months, with a median target of $40.0.

Here are some recent targets:

Steve Beuchaw from Morgan Stanley set a target price of $42.0 on 06/23/2026
Daniel Arias from Stifel set a target price of $36.0 on 05/18/2026
Dan Brennan from TD Cowen set a target price of $40.0 on 05/07/2026
Catherine Schulte from Baird set a target price of $43.0 on 04/29/2026
Luke Sergott from Barclays set a target price of $38.0 on 04/29/2026
Patrick Donnelly from Citigroup set a target price of $38.0 on 04/29/2026
Casey Woodring from JP Morgan set a target price of $45.0 on 04/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.